0001178913-26-001859
SEC filingMediWound Ltd. filed notice of its 2026 Annual General Meeting on May 6, 2026, seeking shareholder approval for re-election of five directors, reappointment of Somekh Chaikin as auditor, and CEO cash bonus for 2025 performance.
This 6-K filing provides the notice and proxy materials for MediWound Ltd.'s 2026 annual general meeting, highlighting standard governance matters. The board proposes re-election of its current five members, all meeting Nasdaq independence standards, with detailed biographies underscoring expertise in biopharma, wound care, M&A, finance, and operations. Exemption from Israeli Companies Law external director requirements remains in effect due to no controlling shareholder and majority independent board. Auditor reappointment continues with Somekh Chaikin since 2021. Proposal 3 for CEO Ofer Gonen's 2025 bonus requires additional Companies Law scrutiny for non-controlling, non-conflicted shareholder approval. No financial results are disclosed here; 2025 Form 20-F was filed March 5, 2026. Meeting quorum needs 25% voting power initially.